Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Research & Development (2016 - 2025)

Abeona Therapeutics has reported Research & Development over the past 15 years, most recently at $6.7 million for Q4 2025.

  • Quarterly results put Research & Development at $6.7 million for Q4 2025, down 25.37% from a year ago — trailing twelve months through Dec 2025 was $26.8 million (down 21.97% YoY), and the annual figure for FY2025 was $26.8 million, down 21.97%.
  • Research & Development for Q4 2025 was $6.7 million at Abeona Therapeutics, up from $4.2 million in the prior quarter.
  • Over the last five years, Research & Development for ABEO hit a ceiling of $12.8 million in Q4 2021 and a floor of $4.2 million in Q3 2025.
  • Median Research & Development over the past 5 years was $8.2 million (2021), compared with a mean of $8.0 million.
  • Biggest five-year swings in Research & Development: soared 39.68% in 2021 and later plummeted 52.85% in 2025.
  • Abeona Therapeutics' Research & Development stood at $12.8 million in 2021, then tumbled by 51.01% to $6.3 million in 2022, then grew by 17.65% to $7.4 million in 2023, then increased by 21.89% to $9.0 million in 2024, then decreased by 25.37% to $6.7 million in 2025.
  • The last three reported values for Research & Development were $6.7 million (Q4 2025), $4.2 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.